Browse the evidence

Semaglutide (2.4 mg once weekly) resulted in weight loss of up to 13.9% after 68 weeks.

Semaglutide is a viable weight loss treatment for adults without diabetes.

GLP-1 receptor agonists and co-agonists are efficacious for weight loss with safety concerns predominantly gastrointestinal.

Practitioners should consider GLP-1 RAs for weight management, noting gastrointestinal side effects.

Long-term adherence to a healthy lifestyle is key in reducing the risk of CVD and diabetes mellitus.

Practitioners should encourage long-term healthy lifestyle changes to reduce chronic disease risk.

Both high and low glycemic load diets resulted in significant reductions in fasting insulin and other insulin dynamics after 6 months.

Both high and low glycemic load diets can effectively reduce insulin levels during weight loss.

The rates of complete and partial diabetes remission were significantly higher in the surgical group compared to the medical group.

Surgical treatment may offer better long-term diabetes management outcomes than medical treatment alone.

Both single-set and multiple-set resistance training produce similar increases in muscular strength, muscle mass, muscle quality, and IGF-1 in untrained older women after 12 weeks.

Practitioners can use either single or multiple sets in resistance training for older women to achieve similar benefits.

Liraglutide effectively reduces body weight and body fat through mechanisms involving reduced appetite and lowered energy intake.

Liraglutide can be considered as a pharmacotherapy option for weight management in patients with obesity.

Semaglutide 2.4 mg weekly significantly reduces Major Adverse Cardiovascular Events (MACE) in obese patients without type 2 diabetes, independent of the magnitude of weight loss.

If you have obesity (BMI ≥ 27) but no diabetes, weekly semaglutide (2.4 mg) is a proven therapy to significantly lower your risk of heart attack, stroke, and cardiovascular death. This benefit happens through direct protection of your blood vessels and reduction of inflammation, not just by making you lose weight. To get the best results, you must pair the medication with a gradual dose increase to minimize stomach issues, and you must actively engage in resistance training and eat enough protein to prevent muscle loss.

GLP1-RA treatment is associated with improvements in restrained eating and emotional eating behavior compared with placebo.

GLP1-RAs may help improve eating behaviors in this population.

Acute post-resistance exercise increases in testosterone (T) and growth hormone (GH) are optimal for maximizing skeletal muscle anabolism and hypertrophy.

Practitioners should consider the importance of T and GH increases in resistance training programs.

Resistance exercise protocols that activate large muscle masses elicit the greatest acute elevations in T and GH.

Design resistance training programs to include large muscle mass exercises for optimal hormonal response.

Obesity as a treatment indication was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 2.46).

Patients with obesity may experience better weight loss outcomes compared to those with type 2 diabetes.

Persistent medication coverage was associated with a higher likelihood of achieving a 10% or greater weight reduction (AOR, 3.36).

Ensuring patients maintain their medication regimen may significantly improve weight loss outcomes.

In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.

Maridebart cafraglutide may be an effective treatment option for weight loss in individuals with obesity.

In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.

Maridebart cafraglutide may also be effective for weight loss in individuals with obesity and type 2 diabetes.

Tirzepatide would avert 45,609 obesity cases per 100,000 individuals over a lifetime.

Tirzepatide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Semaglutide would avert 32,087 obesity cases per 100,000 individuals over a lifetime.

Semaglutide is effective in reducing obesity cases, suggesting its potential use in clinical practice.

Bariatric surgery induces higher rates of short and long-term diabetes remission.

Bariatric surgery may be considered for patients with Type 2 diabetes to improve remission rates.

Insulin and homeostasis model assessment decreased significantly with diet type II in both genotypes.

Diet type II may improve insulin sensitivity in this population.

Glycemic control and hyperinsulinemia are improved by low-carbohydrate diets.

Low-carbohydrate diets may be recommended to improve glycemic control in patients.

Late bedtime was associated with general obesity (AOR, 1.20; 95% CI, 1.12-1.29) and abdominal obesity (AOR, 1.20; 95% CI, 1.12-1.28).

Encouraging earlier bedtimes may help reduce obesity risk.

Short nocturnal sleep of less than 6 hours was associated with general obesity (e.g., <5 hours: AOR, 1.27; 95% CI, 1.13-1.43).

Limiting sleep duration to at least 6 hours may help mitigate obesity risk.

Using tirzepatide resulted in a weight loss of 17.8% compared with 12.4% for semaglutide.

Tirzepatide may be more effective for weight loss in patients with type 2 diabetes.

Multiple risk factors should be targeted simultaneously in T2DM patients to reduce CV events.

A comprehensive approach addressing multiple risk factors is essential for effective cardiovascular disease prevention in T2DM patients.